Tenapanor Reduces Phosphate Levels in Dialysis Patients
A new study shows the medication helps adults on dialysis lower serum phosphate, though gastrointestinal side effects may occur.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Do you prefer to use one medication at a time or combine multiple treatments for health?
A retrospective study of 1477 dialysis patients found that the medication tenapanor significantly reduced serum phosphate levels over six months. These real-world findings were presented this week for patients and clinicians navigating kidney care management.
Why it matters
Managing serum phosphate is critical for dialysis patients to prevent complications, and this study provides insight into how tenapanor performs in a real-world clinical setting compared to standard phosphate binder treatments.
This retrospective study of 1477 dialysis patients analyzed electronic health records to measure serum phosphate levels over six months of treatment. While these findings demonstrate effective reduction, the specific impact on long-term patient health outcomes remains unknown.
The players
ASN Kidney Week 2026
An annual scientific meeting hosted by the American Society of Nephrology focused on advancements in kidney health and research.
The details
Tenapanor works by blocking the absorption of phosphate through the paracellular pathway in the intestine. In clinical trials, the medication is dosed at 30 mg twice daily, though gastrointestinal side effects are common. Specifically, diarrhea has been reported in 43% to 53% of patients, with 5% experiencing severe cases.
Timeline
October 2023: FDA approved tenapanor for clinical use.
November 2023 to June 2025: Patients in the retrospective study initiated tenapanor treatment.
October 21-25, 2026: Findings were presented at ASN Kidney Week 2026 in Denver.
Health Landscape
This research follows a broader trend in nephrology to optimize mineral metabolism beyond traditional binders. It builds on the findings presented at ASN Kidney Week, highlighting the evolution of treatment protocols for patients on long-term dialysis.
Patients using tenapanor should monitor for gastrointestinal side effects like diarrhea, which occurred in up to 53% of clinical trial participants. It is important to discuss any changes in phosphorus management or persistent side effects with your nephrologist.
The takeaway
Real-world data suggests tenapanor can effectively lower serum phosphate for those on dialysis. Patients should be aware of the potential for severe diarrhea and maintain a close dialogue with their care team regarding medication tolerance.
Further reading
For more on managing nutrient absorption and dietary health, visit our Nutrition section.
Live Poll
Do you prefer to use one medication at a time or combine multiple treatments for health?
